Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide Plus DCAG for Relapsed/Refractory AML
NCT02886559Phase 2Unknown
- Sponsor
- Chinese PLA General Hospital
- Start
- Jun 2016
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tucidinostat in acute myeloid leukemia (AML), sponsored by Chinese PLA General Hospital. Status: unknown.
02
Drugs
tucidinostat
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02886559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02886559.